Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin

Abstract

NEUROTENSIN is a tridecapeptide (pGlu–Leu–Tyr–Glu–Asn–Lys–Pro–Arg–Arg–Pro–Tyr–Ile–Leu–COOH)1 isolated from bovine hypothalami2. Using a sensitive and specific radio immunoassay, Carraway and Leeman have demonstrated immunoreactive neurotensin in hypothalamic extracts of rat, mouse, rabbit and human tissue3. Intravenous (i.v.) administration of neurotensin to rats has been reported to cause hypotension (minimum effective dose 100 pmol kg−1 = 0.167 µg kg−1), cyanosis (minimum effective dose 1 nmol kg−1 = 1.67 µg kg−1)2, and hyperglycaemia (minimum effective dose 200 pmol kg−1 = 0.33 µg kg−1)4. These effects are not prevented by adrenalectomy or hypophysectomy. The hypotensive effects are not altered by α- or β-adrenergic blockers. Neurotensin also stimulates the contraction of guinea pig ileum while relaxing rat duodenum in vitro. Neurotensin is as potent as bradykinin in its effects on guinea pig ileum and rat duodenum and thus is classified as a kinin2. It increases plasma gonadotropin levels in ovariectomised, oestrogen–progesterone-treated rats after intravenous injection (minimum effective dose 5 nmol kg−1 = 8.4 µg kg−1)5. Intravenous administration of a dose of 3 µg kg−1 to rats produces hypoinsulinaemia, hyperglycaemia and hyperglucagonaemia6.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Carraway, R. E., and Leeman, S. E., J. biol. Chem., 250, 1907–1911 (1975).

  2. 2

    Carraway, R. E., and Leeman, S. E., J. biol. Chem., 248, 6854–6861 (1973).

  3. 3

    Carraway, R. E., and Leeman, S. E., Fedn Proc., 33, 548 (1974).

  4. 4

    Carraway, R. E., and Leeman, S. E., Fedn Proc., 32, 211 (1973).

  5. 5

    Makino, T., Carraway, R., Leeman, S., and Greep, R. O., Soc. Study Repro., Abstr. No. 26 (1973).

  6. 6

    Brown, M., and Vale, W., Endocrinology, 98, 819–822 (1976).

  7. 7

    Prange, A. J., Jr, et al., Life Sci., 14, 447–455 (1974).

  8. 8

    Prange, A. J., Jr, et al., Life Sci., 16, 1907–1914 (1975).

  9. 9

    Breese, G. R., et al. J. Pharmac. exp. Ther., 193, 11–22 (1975).

  10. 10

    Breese, G. R., et al., Life Sci., 14, 1053–1063 (1974).

  11. 11

    Nemeroff, C. B., Bissette, G., Prange, A. J., Jr, Loosen, P. T., and Lipton, M. A., Proceedings Endocrine Society Annual Meeting, 312 (1976).

  12. 12

    Horita, A., and Carino, M. J., Psychopharm. Commun., 1, 403–414 (1975).

  13. 13

    Metcalf, G., Nature, 252, 310–311 (1974).

  14. 14

    von Euler, U. S., and Gaddem, J. H., J. Physiol., Lond., 72, 74–87 (1931).

  15. 15

    Leeman, S. E., and Mroz, E. A., Life Sci., 15, 2033–2044 (1974).

  16. 16

    Prange, A. J., Jr, Nemeroff, C. B., Lipton, M. A., Breese, G. R., and Wilson, I. C., in Handbook of Psychopharmacology (edit. by Iversen, L. L., Iversen, S. D., and Snyder, S. H.) (Plenum, New York, 1976).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.